La Jolla Pharmaceutical Company has reported a comprehensive net loss attributable to common stockholders of $3.74m, or $0.14 per share, for the second quarter ended on 30 June 2013 compared with $7.77m, or $0.67 per share in 2012. ...
Tags: La Jolla Pharmaceutical, Net Loss
Fujitsu, a leading Japanese information and communication technology (ICT) company, has announced the start of field trials for the production of low-potassium vegetables. Through this field trials, the company plans to produce cultivate ...
Tags: Fujitsu, Low-Potassium Vegetable
Takeda Pharmaceutical Company, AMAG Pharmaceuticals' European commercial partner, has submitted a type-II variation to the European Medicines Agency (EMA) for label expansion of Rienso (ferumoxytol). The approval will allow the use of ...
Tags: Takeda, EMA Approval
UK-based NextPharma Technologies has been selected by Mitsubishi Pharma Europe (MPE) to provide tailored, primary and secondary packaging solutions for its BindRen, within the European territory. MPE, the European subsidiary of Mitsubishi ...
Tags: NextPharma, Packaging
The US Food and Drug Administration (FDA) has accepted for review AMAG Pharmaceuticals' supplemental new drug application (sNDA) for Feraheme (ferumoxytol) injection for Intravenous (IV) use. The sNDA filed is to expand the indication for ...
Tags: FDA, Pharmaceuticals, oral iron treatment
Multinational pharmaceutical and diagnostics company OPKO Health has signed a definitive agreement to acquire Cytochroma. Under the purchase, OPKO intends to include Cytochroma's Replidea and Alpharen, which are in Phase 3 clinical trials ...
Tags: OPKO Health, Cytochroma, CKD, pharmaceutical
Takeda Pharmaceuticals has entered into a deal with US-based DSI Renal for the supply of its OMONTYS (peginesatide) injection, designed for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. ...
Tags: OMONTYS injection, anemia, chronic kidney disease, CKD patients
Japan Tobacco (JT), Keryx Biopharmaceuticals' Japanese partner, has filed a new drug application (NDA) for the marketing approval of Ferric Citrate (Zerenex) in Japan for the treatment of hyperphosphatemia in chronic kidney disease (CKD) ...
Tags: Ferric Citrate, Tobacco, CKD, Pharmaceutical
AMAG Pharmaceuticals has submitted a supplemental new drug application (sNDA) for intravenous (IV) use of Feraheme injection, to FDA. The company is seeking approval for the label expansion of Feraheme to include all iron deficiency ...
Tags: Feraheme Injection, AMAG, SNDA
The Food and Drug Administration (FDA) has accepted Dynavax Technologies' heplisav biologics license application (BLA) for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of ...
Astellas Pharma has received Japanese marketing approval for Kiklin capsules to treat hyperphosphatemia in patients on dialysis with chronic kidney disease. Kiklin capsules, amine-functional polymers, bind to phosphate in the ...
Tags: Kiklin capsules, hyperphosphatemia, chronic kidney disease
Concert Pharmaceuticals has received US patent for CTP-499, its drug candidate being developed for the treatment of diabetic nephropathy. CTP-499 is a potential treatment developed on the basis of DCE Platform for diabetic nephropathy, a ...
US based pharmaceutical company, Amgen has acquired KAI Pharmaceuticals. The acquisition, which was initially announced on 10 April 2012, includes KAI's main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism ...
Astellas Pharma has launched Kiklin capsules 250mg (generic name:Bixalomar) in Japan for the treatment of hyperphosphatemia in patients on dialysis with chronic kidney disease. Kiklin Capsules bind to phosphate in the gastrointestinal ...
AstraZeneca and Ardelyx have signed a worldwide exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The ...
Tags: RDX5791, Ardelyx, AstraZeneca, NHE3 inhibitor programme, NHE3